TNXA and stroke disorder: The NAVIGATE ESUS [New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (ESUS)] trial showed that in patients with an ESUS, there was no significant difference in stroke recurrence between the rivaroxaban and aspirin groups (34).